Validation of immunogenic PASD1 peptides against HLA-A∗24:02 colorectal cancer

Joanne E.C. Soh, Nadiah Abu, Ismail Sagap, Luqman Mazlan, Azyani Yahaya, Muaatamarulain Mustangin, Tze S. Khoo, Sazuita Saidin, Muhiddin Ishak, Nurul S. Ab Mutalib, Rahman Jamal

Research output: Contribution to journalArticle

Abstract

Colorectal cancer is the third commonest malignancy in Asia including Malaysia. The immunogenic cancer-testis antigens, which are expressed in a variety of cancers but with limited expression in normal tissues except the testis, represent an attractive approach to improve treatment options for colorectal cancer. We aimed to validate four PASD1 peptides as the immunotherapeutic targets in colorectal cancer. First, PASD1 mRNA and protein expression were determined via real-time polymerase chain reaction (RT-PCR) and immunohistochemistry. The PASD1 peptides specific to HLA-A*24:02 were investigated using IFN-y-ELISpot assay, followed by the cytolytic and granzyme-B-ELISpot assays to analyze the cytolytic effects of CD8+ T cells. Gene and protein expressions of PASD1 were detected in 20% and 17.3% of colorectal cancer samples, respectively. PASD1(4) peptide was shown to be immunogenic in colorectal cancer samples. CD8+ T cells raised against PASD1(4) peptide were able to lyze HLA-A*24:02+ PASD1+ cells. Our results reveal that PASD1(4) peptide represents a potential target for colorectal cancer.

Original languageEnglish
Pages (from-to)1205-1219
Number of pages15
JournalImmunotherapy
Volume11
Issue number14
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

HLA-A24 Antigen
Colorectal Neoplasms
Peptides
T-Lymphocytes
Granzymes
Malaysia
Testicular Neoplasms
Testis
Real-Time Polymerase Chain Reaction
Neoplasms
Proteins
Immunohistochemistry
Gene Expression
Antigens
Messenger RNA

Keywords

  • 2402
  • cancer-testis antigen
  • cytotoxic T cell
  • HLA-A
  • immunotherapy
  • peptide

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Validation of immunogenic PASD1 peptides against HLA-A∗24:02 colorectal cancer. / Soh, Joanne E.C.; Abu, Nadiah; Sagap, Ismail; Mazlan, Luqman; Yahaya, Azyani; Mustangin, Muaatamarulain; Khoo, Tze S.; Saidin, Sazuita; Ishak, Muhiddin; Ab Mutalib, Nurul S.; Jamal, Rahman.

In: Immunotherapy, Vol. 11, No. 14, 01.01.2019, p. 1205-1219.

Research output: Contribution to journalArticle

Soh, Joanne E.C. ; Abu, Nadiah ; Sagap, Ismail ; Mazlan, Luqman ; Yahaya, Azyani ; Mustangin, Muaatamarulain ; Khoo, Tze S. ; Saidin, Sazuita ; Ishak, Muhiddin ; Ab Mutalib, Nurul S. ; Jamal, Rahman. / Validation of immunogenic PASD1 peptides against HLA-A∗24:02 colorectal cancer. In: Immunotherapy. 2019 ; Vol. 11, No. 14. pp. 1205-1219.
@article{bac092c156024485a718428df4b3c4ff,
title = "Validation of immunogenic PASD1 peptides against HLA-A∗24:02 colorectal cancer",
abstract = "Colorectal cancer is the third commonest malignancy in Asia including Malaysia. The immunogenic cancer-testis antigens, which are expressed in a variety of cancers but with limited expression in normal tissues except the testis, represent an attractive approach to improve treatment options for colorectal cancer. We aimed to validate four PASD1 peptides as the immunotherapeutic targets in colorectal cancer. First, PASD1 mRNA and protein expression were determined via real-time polymerase chain reaction (RT-PCR) and immunohistochemistry. The PASD1 peptides specific to HLA-A*24:02 were investigated using IFN-y-ELISpot assay, followed by the cytolytic and granzyme-B-ELISpot assays to analyze the cytolytic effects of CD8+ T cells. Gene and protein expressions of PASD1 were detected in 20{\%} and 17.3{\%} of colorectal cancer samples, respectively. PASD1(4) peptide was shown to be immunogenic in colorectal cancer samples. CD8+ T cells raised against PASD1(4) peptide were able to lyze HLA-A*24:02+ PASD1+ cells. Our results reveal that PASD1(4) peptide represents a potential target for colorectal cancer.",
keywords = "2402, cancer-testis antigen, cytotoxic T cell, HLA-A, immunotherapy, peptide",
author = "Soh, {Joanne E.C.} and Nadiah Abu and Ismail Sagap and Luqman Mazlan and Azyani Yahaya and Muaatamarulain Mustangin and Khoo, {Tze S.} and Sazuita Saidin and Muhiddin Ishak and {Ab Mutalib}, {Nurul S.} and Rahman Jamal",
year = "2019",
month = "1",
day = "1",
doi = "10.2217/imt-2019-0073",
language = "English",
volume = "11",
pages = "1205--1219",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "14",

}

TY - JOUR

T1 - Validation of immunogenic PASD1 peptides against HLA-A∗24:02 colorectal cancer

AU - Soh, Joanne E.C.

AU - Abu, Nadiah

AU - Sagap, Ismail

AU - Mazlan, Luqman

AU - Yahaya, Azyani

AU - Mustangin, Muaatamarulain

AU - Khoo, Tze S.

AU - Saidin, Sazuita

AU - Ishak, Muhiddin

AU - Ab Mutalib, Nurul S.

AU - Jamal, Rahman

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Colorectal cancer is the third commonest malignancy in Asia including Malaysia. The immunogenic cancer-testis antigens, which are expressed in a variety of cancers but with limited expression in normal tissues except the testis, represent an attractive approach to improve treatment options for colorectal cancer. We aimed to validate four PASD1 peptides as the immunotherapeutic targets in colorectal cancer. First, PASD1 mRNA and protein expression were determined via real-time polymerase chain reaction (RT-PCR) and immunohistochemistry. The PASD1 peptides specific to HLA-A*24:02 were investigated using IFN-y-ELISpot assay, followed by the cytolytic and granzyme-B-ELISpot assays to analyze the cytolytic effects of CD8+ T cells. Gene and protein expressions of PASD1 were detected in 20% and 17.3% of colorectal cancer samples, respectively. PASD1(4) peptide was shown to be immunogenic in colorectal cancer samples. CD8+ T cells raised against PASD1(4) peptide were able to lyze HLA-A*24:02+ PASD1+ cells. Our results reveal that PASD1(4) peptide represents a potential target for colorectal cancer.

AB - Colorectal cancer is the third commonest malignancy in Asia including Malaysia. The immunogenic cancer-testis antigens, which are expressed in a variety of cancers but with limited expression in normal tissues except the testis, represent an attractive approach to improve treatment options for colorectal cancer. We aimed to validate four PASD1 peptides as the immunotherapeutic targets in colorectal cancer. First, PASD1 mRNA and protein expression were determined via real-time polymerase chain reaction (RT-PCR) and immunohistochemistry. The PASD1 peptides specific to HLA-A*24:02 were investigated using IFN-y-ELISpot assay, followed by the cytolytic and granzyme-B-ELISpot assays to analyze the cytolytic effects of CD8+ T cells. Gene and protein expressions of PASD1 were detected in 20% and 17.3% of colorectal cancer samples, respectively. PASD1(4) peptide was shown to be immunogenic in colorectal cancer samples. CD8+ T cells raised against PASD1(4) peptide were able to lyze HLA-A*24:02+ PASD1+ cells. Our results reveal that PASD1(4) peptide represents a potential target for colorectal cancer.

KW - 2402

KW - cancer-testis antigen

KW - cytotoxic T cell

KW - HLA-A

KW - immunotherapy

KW - peptide

UR - http://www.scopus.com/inward/record.url?scp=85072368963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072368963&partnerID=8YFLogxK

U2 - 10.2217/imt-2019-0073

DO - 10.2217/imt-2019-0073

M3 - Article

C2 - 31478431

AN - SCOPUS:85072368963

VL - 11

SP - 1205

EP - 1219

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 14

ER -